Blenrep (belantamab mafodotin-blmf)
GSK (GlaxoSmithKline) · BCMA-Targeted Antibody-Drug Conjugate (ADC)
What is Blenrep? Blenrep (belantamab mafodotin-blmf) is a BCMA-targeted antibody-drug conjugate by GSK that delivers MMAF (a microtubule inhibitor) to BCMA-expressing multiple myeloma cells. It is approved for relapsed or refractory multiple myeloma after prior therapies.
About Blenrep
| Brand Name | Blenrep |
| Generic / INN | belantamab mafodotin-blmf |
| Drug Class | BCMA-Targeted Antibody-Drug Conjugate (ADC) |
| Manufacturer | GSK (GlaxoSmithKline) |
| Administration | Intravenous (IV) infusion |
| FDA Approval | 2020 |
FDA-Approved Uses
- Relapsed or refractory multiple myeloma — adults who have received at least 4 prior lines of therapy including an anti-CD38 monoclonal antibody, a proteasome inhibitor, and an immunomodulatory agent
How Does Blenrep Work?
Belantamab mafodotin uses an anti-BCMA antibody to deliver MMAF (monomethyl auristatin F) directly to BCMA-expressing myeloma cells. After internalization and linker cleavage, MMAF inhibits microtubule polymerization causing mitotic arrest and apoptosis. Unlike MMAE (used in brentuximab), MMAF is less membrane-permeable, limiting bystander effects.
Dosage & Administration
2.5 mg/kg IV over approximately 30 minutes every 3 weeks. Eye exam (including visual acuity) required before each dose. Dose modifications based on ocular toxicity severity.
Dosing is individualized by the treating oncologist. Do not adjust without medical guidance. This page is educational only.
Warnings & Side Effects
- Ocular toxicity (keratopathy) — REMS required; eye exam before each dose
- Severe thrombocytopenia
- Infusion-related reactions
- Embryo-fetal toxicity
Common Side Effects
- Keratopathy/corneal changes (very common)
- Blurred vision
- Thrombocytopenia
- Anemia
- Fatigue
- Nausea
- Dry eye
- Photophobia
Storage & Handling
Refrigerate at 2°C to 8°C (36°F to 46°F). Do not freeze. Protect from light.
💰 Medication Cost & Insurance Coverage
Approximate Wholesale Acquisition Cost (WAC / List Price)
~$16,000–$20,000/dose
2.5 mg/kg every 3 weeks
Insurance & Prior Authorization
Blenrep requires prior authorization from all major insurance plans. BiologicHealthPlus handles the full PA process — clinical documentation, peer-to-peer reviews, and appeals — at no cost to patients or providers.
Prior Authorization Guide Patient Assistance Insurance & Savings
Frequently Asked Questions — Blenrep
Blenrep is a BCMA-targeted ADC by GSK that delivers MMAF chemotherapy directly into BCMA-expressing myeloma cells. Approved after 4+ prior lines of therapy.
Keratopathy (corneal epithelial changes) occurs in the majority of patients and can cause blurred vision, dry eyes, and light sensitivity. Eye exams are required before every dose through the REMS program.
The SIGHT REMS program restricts Blenrep to certified healthcare facilities with access to certified eye care providers. Patients must receive ophthalmology evaluation before each dose.
Blenrep is covered by Medicare Part B and commercial insurance for eligible myeloma patients with prior authorization and documentation of prior therapy lines.
Related Medications & Conditions
Related Medications
Abecma (idecabtagene vicleucel — CAR-T BCMA) · Carvykti · Darzalex (daratumumab) · Velcade (bortezomib) · Revlimid
Related Conditions
Multiple myeloma · Relapsed/refractory myeloma · BCMA-expressing plasma cell malignancies